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Glycine receptors (GlyRs) and specific subtypes of GABAA receptors are clustered at synapses by the multidomain protein gephyrin,
which in turn is translocated to the cell membrane by the GDP–GTP exchange factor collybistin. We report the characterization of several
new variants of collybistin, which are created by alternative splicing of exons encoding an N-terminal src homology 3 (SH3) domain and
three alternate C termini (CB1, CB2, and CB3). The presence of the SH3 domain negatively regulates the ability of collybistin to translocate
gephyrin to submembrane microaggregates in transfected mammalian cells. Because the majority of native collybistin isoforms appear
to harbor the SH3 domain, this suggests that collybistin activity may be regulated by protein–protein interactions at the SH3 domain. We
localized the binding sites for collybistin and the GlyR  subunit to the C-terminal MoeA homology domain of gephyrin and show that
multimerization of this domain is required for collybistin– gephyrin and GlyR– gephyrin interactions. We also demonstrate that gephy-
rin clustering in recombinant systems and cultured neurons requires both collybistin– gephyrin interactions and an intact collybistin
pleckstrin homology domain. The vital importance of collybistin for inhibitory synaptogenesis is underlined by the discovery of a
mutation (G55A) in exon 2 of the human collybistin gene (ARHGEF9) in a patient with clinical symptoms of both hyperekplexia and
epilepsy. The clinical manifestation of this collybistin missense mutation may result, at least in part, from mislocalization of gephyrin and
a major GABAA receptor subtype.
Key words: dendritic transport; epilepsy; GABAA receptor; glycine receptor; hyperekplexia; trafficking
Introduction
Inhibitory neurotransmission relies on glycine and GABA recep-
tors being clustered at postsynaptic specializations opposite axon
terminals releasing the corresponding neurotransmitters. Cen-
tral to this arrangement is gephyrin, which colocalizes with gly-
cine receptors (GlyRs) at inhibitory synapses (Triller et al., 1985;
Schmitt et al., 1987). Gephyrin can interact with polymerized
tubulin (Kirsch et al., 1991), the GlyR  subunit (Kneussel et al.,
1999a), profilin (Mammoto et al., 1998), RAFT-1 (rapamycin
and FKBP target-1) (Sabatini et al., 1999), dynein light chains 1
and 2 (Fuhrmann et al., 2002), and Mena (mammalian enabled)/
VASP (vasodilator stimulated phosphoprotein) (Giesemann et
al., 2003). In addition, gephyrin is also essential for the postsyn-
aptic clustering of GABAA receptors containing 2 or 3 sub-
units (Essrich et al., 1998; Kneussel et al., 1999b, 2001b; Levi et al.,
2004). A selective loss of synaptic GABAA receptors in 2 subunit
mutant mice also results in the loss of gephyrin clusters (Essrich
et al., 1998; Schweizer et al., 2003), indicating some interdepen-
dence for their synaptic localization. Interestingly, when ex-
pressed in mammalian cells, gephyrin forms cytoplasmic aggre-
gates (Kirsch et al., 1995), suggesting that other “factors” are
required to direct gephyrin to submembrane microaggregates.
The preliminary characterization of collybistin (Kins et al., 2000;
Grosskreutz et al., 2001), a novel gephyrin-associated GDP–GTP
exchange factor (GEF), presented a plausible mechanism(s) by
which gephyrin could be targeted to synapses.
Collybistin is a member of the guanine nucleotide exchange
factor superfamily, which catalyzes GDP–GTP exchange on small
GTPases of the Rho family (Wherlock and Mellor, 2002). GEFs
are characterized by tandem exchange factor (RhoGEF) and
pleckstrin homology (PH) domains. The RhoGEF domain cata-
lyzes the exchange reaction, whereas the PH domain can bind
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with high affinity to membrane phosphoinositides, thus restrict-
ing GEF localization and activity to the submembrane compart-
ment (Kavran et al., 1998). Collybistin was initially found in two
isoforms created by alternative splicing: “collybistin I,” which
contains an N-terminal src homology 3 (SH3) domain and a
C-terminal coiled-coil domain, and “collybistin II,” which lacks
the SH3 domain and has an alternate C terminus. On expression
in human embryonic kidney (HEK) 293 cells, collybistin I colo-
calized with intracellular gephyrin aggregates, whereas collybistin
II enabled translocation of gephyrin to submembrane microag-
gregates (Kins et al., 2000). The human homolog of collybistin,
hPEM-2 (human homolog of Posterior End Mark-2), appears to
activate the GTPase Cdc42 (Reid et al., 1999), which influences
cell morphology by initiating actin cytoskeleton remodeling
(Erickson and Cerione, 2001). It has been proposed that at inhib-
itory synapses, collybistin initiates local remodeling of the sub-
synaptic cytoskeleton (Kneussel and Betz, 2000).
In this study, we investigated the diversity of collybistin iso-
forms generated by alternative splicing and the role of the SH3,
RhoGEF, and PH domains in translocating gephyrin to submem-
brane microaggregates. We also mapped the binding sites for
collybistin and the GlyR subunit on gephyrin. This information
was used to evaluate ARHGEF9 as a candidate gene for hyperek-
plexia in a cohort of 32 patients without mutations in the GlyR1
and  subunit genes or gephyrin (Rees et al., 2001, 2002, 2003).
Examination of naturally occurring and artificial mutants of col-
lybistin emphasizes the importance of this RhoGEF for postsyn-
aptic localization of gephyrin and inhibitory ligand-gated ion
channels.
Materials and Methods
Amplification, cloning, and sequencing of rat and human collybistin
cDNAs. Rat collybistin cDNAs were amplified from postnatal day (P) 0
rat spinal cord and whole-brain first-strand cDNA using the primer combi-
nations r1: 5-GTGGGATCCATGCAGTGGATTAGAGGCGGA-3 plus
r2: 5-TTCGAATTCCCCATCCTCCTGGTTCACCCA-3 and r3 5-GGA-
GGATCCAATACGTTGGCTTAGAGCTTT-3 plus r4 5-TTAGAA-
TTCTCTGCCTTCCTATAGGTATTA-3. Human collybistin cDNAs
were amplified from human whole-brain or spinal cord cDNA (Clontech,
Cambridge, UK) using the primer combinations h1: 5-CATGGCCTCG-
CTGTGATATGTATG-3 plus h2: 5-TCCAGGTGTCCGTTCTGCAC-
ATCG-3 or h3 5-CTGCAATGACTGTGAGAAAAGTCC-3 plus h4
5-ATTATCTGCCTCCCTGTAGGTATC-3. Amplifications were per-
formed under semiquantitative conditions using Pfu Turbo proofreading
DNA polymerase (Stratagene, La Jolla, CA) and 30 cycles of 94°C for 1
min, 65°C for 1 min, and 68°C for 3 min. PCR products were cloned into
the pCR4 Blunt TOPO vector (Invitrogen, San Diego, CA), and plasmid
DNAs were made using spin miniprep and maxi kits (Qiagen, Hilden,
Germany). Plasmid inserts were fully sequenced using the BigDye ready
reaction mix (PerkinElmer Life Sciences, Emeryville, CA) and an Applied
Biosystems (Foster City, CA) 310 automated DNA Sequencer.
Functional assays of collybistin– gephyrin interactions in HEK293 cells.
pRK5myc-CB2SH3, pRK5myc-CB2SH3, and pRK5myc-CB3SH3: colly-
bistin cDNAs were amplified from P0 rat brain first-strand cDNA using
the primers r1 and r4 (see above) and cloned into the BamHI and EcoRI
sites of the vector pRK5myc so that a 9E10 (myc) tag is attached to the N
terminus. Deletions of the SH3, RhoGEF, and PH domains were made in
pRK5myc-CB2SH3 using the Quikchange site directed mutagenesis kit
(Stratagene). pEGFP-gephyrin: the entire coding region of the rat gephy-
rin P1 isoform (Prior et al., 1992) was amplified from P0 rat brain first-
strand cDNA using the primers rGeph1 5-CGCTGATCAACAT-
GGCGACCGAGGGA-3 and rGeph2 5-TGGCTCGAGTCATAGCC-
GTCCGATGA-3, cut with BclI and XhoI, and cloned into the BglII and
SalI sites of pEGFP-C2 (Clontech), so that the enhanced green fluores-
cent protein (EGFP) tag is N terminal. pDsRed-GlyR : the large intra-
cellular loop of the human GlyR  subunit (Handford et al., 1996) was
amplified using the primers hDsRed1 5-GCTGAATTCGCCAC-
CATGGCAGTTGTCCAGGTGATGCT-3 and hDsRed2 5-AAC-
GGATCCCTTGCATAAAGATCAATTCGC-3 and cloned into the
EcoRI and BamHI sites of pDSRedN1 (Clontech), so that the DsRed tag is
C terminal. Amplifications were performed using Pfu Turbo DNA poly-
merase, and all plasmids were sequenced to confirm the veracity of the
constructs. HEK293 cells (CRL1573; American Type Culture Collection,
Manassas, VA) were grown in DMEM supplemented with 10% (v/v) fetal
bovine serum (FBS), 2 mM glutamine, 100U/ml penicillin G, and 100
g/ml streptomycin at 37°C in 95% air–5% CO2 (Harvey et al., 1999).
Exponentially growing cells were electroporated (400 V; infinite resis-
tance, 125 F; Gene Electropulser II; Bio-Rad, Hercules, CA) with vari-
ous combinations of the plasmid constructs. For cotransfections (e.g.,
myc-CB2SH3 plus EGFP-gephyrin), plasmids were used at a ratio of 1:1.
After 24 hr, cells were washed twice in PBS and fixed for 5 min in 4%
(w/v) paraformaldehyde (PFA) in PBS. Myc-tagged CB2SH3, CB2SH3,
and CB3SH3 proteins were detected using an anti-9E10 monoclonal anti-
body (mAb) (Sigma, St. Louis, MO) and tetramethylrhodamine
isothiocyanate- or cyanin 5 (Cy5)-conjugated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA) using standard protocols.
Confocal microscopy was performed as described previously (Dunne
et al., 2002).
Culture, transfection, and immunostaining of cortical neurons. Cortical
neurons were cultured from embryonic day (E) 14 mice. Cortical hemi-
spheres were collected in PBS, pH 7.4, containing 5.5 mM glucose and
treated with papain (0.5 mg/ml; Sigma) and DNase I (10 g/ml) in PBS
containing 1 mg/ml bovine serum albumin and 10 mM glucose for 15 min
at room temperature. The cells were mechanically triturated and then
plated on poly-L-lysine-coated glass coverslips at 4  10 4 cells/cm 2 in
modified Eagle medium (Invitrogen) containing 10% (v/v) FBS, which
was replaced after 60 min. After 24 hr, the coverslips were turned upside
down onto a glial feeder layer in a Petri dish containing Neurobasal-A
supplemented with B27 (Invitrogen). Neurons were transfected at 18 d in
vitro (DIV) using a calcium coprecipitation transfection kit (BD Bio-
sciences, Palo Alto, CA). Briefly, the coverslips were reinverted and trans-
ferred into new Petri dishes containing glia-conditioned Neurobasal
A/B27 supplemented with 0.8 mg/ml NaHCO3, 1 M 6-cyano-7-
nitoquinoxaline-2,3-dione (Sigma), and 100 M 2-amino-5-phospho-
novaleric acid (Sigma). Plasmid DNA (10 g/coverslip) was mixed with
12.4l of 2 M CaCl2 to a final volume of 100l and then added slowly to
an equal volume of 2HEPES-buffered saline while thoroughly mixing.
The DNA was allowed to precipitate for 15 min, added to the cells, and
incubated for 45 min. The coverslips were then returned to the original
dishes containing conditioned medium and used for immunocytochem-
istry at 21 DIV.
Neurons on coverslips were rinsed with PBS, fixed with 4% (w/v) PFA
in 150 mM sodium phosphate buffer, pH 7.4, for 15 min, permeabilized
for 5 min with 0.15% saponin in PBS containing 10% (v/v) normal
donkey serum, and incubated overnight at 4°C with combinations of
primary antibody to the myc tag of collybistin constructs (rabbit poly-
clonal anti-Myc Tag; Medical and Biological Laboratories, Nahgoya, Ja-
pan), gephyrin (mAb7a; Alexis Biochemicals, San Diego, CA), or glu-
tamic acid decarboxylase (mAb GAD-6; Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA) and the GABAA
receptor 2 subunit (raised in guinea pigs) (Fritschy and Mohler, 1995)
in PBS containing 0.15% (v/v) saponin and 10% (v/v) normal donkey
serum. Note that for experiments with EGFP-gephyrin constructs,
mAb7a is assumed to recognize both native and recombinant gephyrin.
The cells were washed in PBS containing 0.15% (v/v) saponin and then
incubated with secondary antibody raised in the proper species and con-
jugated to AlexaFluor 488 (Molecular Probes, Eugene, OR), Cy3, or Cy5
(Jackson ImmunoResearch) in PBS containing 0.15% (v/v) saponin and
10% (v/v) normal donkey serum. Epifluorescent images were captured
using a Zeiss (Thornwood, NY) Axiophot2 microscope equipped with a
1.3 differential interference contrast 40 objective and an ORCA-100
cooled CCD camera linked to an Openlab imaging system (Improvision,
Lexington, MA).
Quantitation of immunofluorescence images. To quantify the effects of
transfecting wild-type or mutant collybistin and gephyrin constructs into
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neurons, two dendritic segments of 40 m length were selected per cell
(for 10 –12 transfected cells per construct) that exhibited low overall
background staining for gephyrin (mAb7a) or the GABAA receptor 2
subunit. Immunoreactive puncta (size range, 0.2–2 m in diameter) in
each segment were automatically selected by setting a fluorescence inten-
sity threshold that was twofold greater than the diffuse fluorescence on
dendritic shafts within the region of interest. The average number of
gephyrin (mAb7a) clusters was determined by counting the number of
immunoreactive puncta within the correct size range per 40m segment
per cell. The number of GABAA receptor clusters (punctate 2 immuno-
reactivity) was determined identically on dendritic segments that were
innervated by GABAergic terminals (as judged by GAD staining). Anal-
ysis was performed using Openlab imaging software with Microsoft (Se-
attle, WA) Excel. Student’s two-tailed t test was used for all statistical
comparisons.
Mapping binding sites on gephyrin using the GAL4 yeast two-hybrid system.
To identify putative domains of gephyrin, which interact with the colly-
bistin and the GlyR  subunit, several baits were cloned into the GAL4
binding domain vector pYTH9, which can be integrated into the trp locus
for stable expression of fusion proteins (Fuller et al., 1998). pYTH9-
CB2SH3: pRK5myc-CB2SH3was cut with NcoI and EcoRI to release the
full-length cDNA, and this was cloned into the corresponding sites in
pYTH9. pYTH9-GlyR: the large intracellular loop of the human GlyR
subunit (Handford et al., 1996) was amplified using the primers hGlyR1
5-GGTGTCGACGAACAACCCCAAAAGGGTTGA-3 and hGlyR2
5-AGGGAATTCTCATCTTGCATAAAGATCAAT-3 and cloned into the
SalI and EcoRI sites of pYTH9. pYTH9-MoeA: the “MoeA homology do-
main” from the rat gephyrin P1 isoform (Prior et al., 1992) was amplified
using the primers rGeph3 5-AGCGTCGACCAGTGCTGTAGATATCA-3
and rGeph4 5-TGGCCGCGGTCATAGCCGTCCGATGACCA-3 and
cloned into the SalI and SacII sites of pYTH9. Fragments of the rat gephyrin
P1 isoform cDNA were amplified using multiple oligonucleotide primers
and were cloned into the vector pACT2 (Clontech). As above, amplifications
were performed using Pfu Turbo DNA polymerase, and all constructs were
fully sequenced. Cotransformed yeast were plated on selective dropout me-
dia lacking leucine and tryptophan (Clontech) and incubated at 30°C for
3–6 d to allow prototropic colonies to emerge. LacZ reporter gene assays
were performed as described previously (Fuller et al., 1998).
Collybistin gene structures and analysis in hyperekplexia patients. Hu-
man collybistin cDNAs (Reid et al., 1999; our study) were submitted for
Basic Local Alignment Search Tool (BLAST)-like alignment tool searches
of the University of California Santa Cruz Genome Browser Database
(Karolchik et al., 2003) (http://genome.ucsc.edu/). Intron– exon organi-
zations were established from comparisons of cloned cDNAs, spliced
expressed sequence tags (ESTs) and genomic sequences. The majority of
patients included in the mutation analysis of the human collybistin gene
(ARHGEF9) are described previously (Rees et al., 2001). An additional
seven unrelated hyperekplexia patients were also analyzed; all conform to
the diagnostic criteria of inclusion, which involves a history of neonatal
hypertonia, a nose tap response, and an exaggerated startle response
leading to injurious fall down consequences with preservation of con-
sciousness (Andrew and Owen, 1997). Exons and flanking intronic se-
quences, plus 5 and 3untranslated regions, were amplified from patient
DNAs using the primers detailed in supplemental Table 1 (available at
www.jneurosci.org) (Rees et al., 2001, 2002). Each 25 l reaction con-
tained 60 ng of genomic DNA, 10 pmol of each primer, 1.5 mM MgCl2, 50
mM KCl, 10 mM Tris-HCl, pH 8.3, 200 M dNTPs (Amersham Bio-
sciences, Arlington Heights, IL), and 1 U Taq polymerase (Qiagen). PCR
conditions consisted of an initial denaturation at 94°C for 5 min followed
by 35 cycles of 30 sec at 94°C, 30 sec at 60°C, and 30 sec at 72°C. Mutation
analysis of PCR products was performed using Transgenomic dHPLC
HT-WAVE R DNA Fragment Analysis System, using DNASep R columns
(Transgenomic, Omaha, NE). The program dHPLCMelt was used to
predict the optimal melting conditions for PCR fragments, and the
WAVE instrument was run under partially denaturing conditions for
mutation detection and single-nucleotide polymorphism (SNP) discov-
ery. Because of the X-linked localization of ARHGEF9, all male patient
PCRs were combined with a sequence-verified female DNA control.
Variant dHPLC profiles suggestive of allelic heterogeneity were gel iso-
lated (Qiagen) and sequenced using ABI3100 technology. The G55A
mutant was introduced into pRK5myc-CB3SH3 using the Quikchange
site-directed mutagenesis kit (Stratagene).
Results
Multiple collybistin isoforms are generated by
alternative splicing
Yeast two-hybrid screening with gephyrin originally identified
two collybistin isoforms, which were created by alternative splic-
ing of primary transcripts (Kins et al., 2000). Alternative splicing
of collybistin mRNAs appears to have functional relevance, be-
cause only collybistin II is able to translocate gephyrin to sub-
membranous microaggregates (Kins et al., 2000). We performed
reverse transcriptase (RT)-PCR assays from rodent– human spi-
nal cord and whole-brain cDNAs to assess the relative abundance
of different collybistin transcripts. DNA sequence analysis of
both amplified and published cDNAs (Kins et al., 2000) revealed
that three different collybistin C termini can be specified in the rat
by the use of different cassette exons (Fig. 1A–D). Collybistin I
(GRVGEEENQSLELKRACEVLQRLWSPGKKS*) and collybis-
tin II (VTQRKWHY*) C termini are generated by insertion of
either 109 or 62 bp exons into collybistin transcripts (Fig. 1A,C).
When neither exon is used, a third C terminus is specified, which
shares 59 of 60 residues with the C terminus of human colly-
bistin (hPEM-2) (Reid et al., 1999). In contrast, the exon en-
coding the N-terminal SH3 domain is used in the majority of
rodent and human collybistin brain mRNAs (Fig. 1 B). Splic-
ing of this exon did not alter during postnatal development in
mouse brain (Fig. 1 B).
Accordingly, we renamed these collybistin isoforms CB1 (col-
lybistin I), CB2 (collybistin II), and CB3 (hPEM2-like) and also
denoted SH3 domain usage (e.g., CB2SH3 or CB2SH3). In post-
natal rodent spinal cord and brain, our RT-PCR assays predict
that the CB2SH3 and CB3SH3 isoforms are predominant (Fig.
1B,C). CB1 isoforms were not detected in any of our rodent
mRNAs but might be expressed in different tissues or at other
developmental stages. To confirm these results, we cloned and
sequenced full-length cDNAs for rat collybistin from rat whole-
brain mRNA. Only CB2SH3 and CB3SH3 cDNAs were found in
a ratio of 5:4 (nine independent isolates). In human brain and
spinal cord, only the CB3SH3 isoform was present; transcripts
encoding CB1 and CB2 variants were not detected (Fig. 1C). Last,
BLAST analysis revealed that rat collybistins and hPEM-2 are
most closely related to ARHGEF4 (ASEF/KIAA1112) (Kawasaki
et al., 2000), Tiam-1 (Habets et al., 1994; Worthylake et al., 2000),
and PIX/p85Cool-1 (Bagrodia et al., 1998; Manser et al., 1998),
all of which specifically activate the GTPase Rac1 but not Cdc42.
Functional domains of collybistin required for gephyrin
submembrane targeting
Full-length cDNAs for CB2SH3 and CB3SH3 (supplemental Fig.
1, available at www.jneurosci.org) were tagged with the 9E10
epitope at the N terminus of the expressed protein. To test the
activity of these recombinant collybistin isoforms, we also created
a plasmid construct (pEGFP-gephyrin) in which EGFP is fused to
the N terminus of gephyrin (P1 isoform) (Prior et al., 1992). This
allows discrimination of living cells possessing extensive sub-
membrane microaggregates from those showing intracellular
gephyrin deposits (Kins et al., 2000) using fluorescence micros-
copy. When transfected into HEK293 cells, myc-CB2SH3 is dif-
fusely distributed throughout the cytoplasm (Fig. 1E). Although
they were not serum-starved, some cells showing high levels of
myc staining exhibited filopodia (MacKay and Hall, 1998),
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whereas others also displayed membrane ruffling (Fig. 1E). In
contrast, EGFP-gephyrin expression resulted in the formation of
large intracellular deposits (Fig. 1F), which are consistent with
those observed using nontagged gephyrin (Kirsch et al., 1995).
Coexpression of CB2 isoforms with EGFP-gephyrin revealed that
the common SH3-containing variant (myc-CB2SH3) behaved
exactly like collybistin I (Kins et al., 2000) and redistributed to
large intracytoplasmic EGFP-gephyrin aggregates (Fig. 1G). In
contrast, the variant lacking the SH3 do-
main (myc-CB2SH3), redistributed with
EGFP-gephyrin to submembrane micro-
aggregates in 40% of cotransfected cells
(Fig. 1H, I), whereas others demonstrated
different phenotypes (e.g., intracellular
aggregates with extended filamentous
structures; data not shown). Transfection
of HEK293 cells with myc-CB2SH3,
EGFP-gephyrin and red fluorescent
protein-conjugated GlyR  subunit intra-
cellular loop (DsRed-GlyR ) resulted in
collybistin-mediated translocation of
EGFP-gephyrin to submembrane clusters
that were also decorated by DsRed-GlyR 
(Fig. 2A–D). However, it is noteworthy
that the expression of myc-CB2SH3 was
not restricted to EGFP-gephyrin/DsRed-
GlyR  clusters (Fig. 2C,D).
Functional analyses of collybistin
isoforms and mutants in
transfected neurons
To assess the possible contribution of col-
lybistin to endogenous gephyrin cluster-
ing, we transfected selected collybistin
constructs into cultured cortical neurons.
Although collybistin has been speculated
to represent a synaptic protein (Kins et al.,
2000; Kneussel and Betz, 2000), we found
myc-CB2SH3 and myc-CB2SH3 to be
diffusely distributed throughout the soma
and dendrites of transfected cortical neu-
rons (Fig. 3A–D). Recombinant myc-
CB2SH3 and myc-CB2SH3 did not sig-
nificantly affect endogenous gephyrin
clustering (Fig. 3E). For myc-CB2SH3 the
average number of gephyrin clusters was
9.96  2.13 per 40 m segment per cell
versus 9.86  2.27 for myc-CB2SH3 (n  11 neurons per con-
struct). The average cluster size was 1.60  0.84 m for myc-
CB2SH3 versus 1.39 0.47 for myc-CB2SH3 (n 11 neurons
per construct). We next attempted to construct dominant-
negative mutants of CB2 (Fig. 3, inset) to test the proposed func-
tion of collybistin in gephyrin clustering in neurons. Deletions of
the RhoGEF domain (amino acids 114 –293) or the PH domain
(amino acids 326 – 432) were made in the CB2SH3 isoform. On
expression in HEK293 cells, deletion of the RhoGEF domain
(myc-CB2SH3 RhoGEF) abolished gephyrin-collybistin colo-
calization and EGFP-gephyrin submembrane targeting (Fig.
3F,G). In contrast, deletion of the PH domain in myc-CB2SH3
(i.e., myc-CB2SH3 PH) resulted in the production of cytoplas-
mic collybistin-gephyrin aggregates (Fig. 3H, I), indicating that
the PH domain was required for normal targeting of this protein.
As expected, myc-CB2SH3 PH also interfered effectively with
clustering of gephyrin in neurons: dendritic clusters of endoge-
nous gephyrin (as visualized by immunostaining with mAb7a)
were almost completely eliminated after expression of this dele-
tion mutant (Fig. 3 J,K). The average number of gephyrin clusters
for myc-CB2SH3 PH was significantly reduced to 2.1  1.13
clusters per 40 m segment per cell (n  10 neurons) (Fig. 3E),
when compared with either myc-CB2SH3 or myc-CB2SH3
( p 	 0.001; Student’s t test). Thus, myc-CB2SH3 PH effec-
Figure 1. Alternative splicing of rat and human collybistin mRNAs. Three different collybistin C termini can be specified in the
rat by the use of different cassette exons. For example, the CB2 (VTQRKWHY*) C terminus is generated by insertion of a 62 bp exon
(A, white lettering on black background). When omitted, an alternative C terminus is specified (CB3) that is virtually identical to
the C terminus of human collybistin (hPEM-2). RT-PCR analysis shows that the exon encoding the N-terminal SH3 domain ( B) is
used in most rodent and human collybistin mRNAs (E, SH3;▫, SH3). For C-terminal exons ( C), both CB2 (E) and CB3 (▫) are
common in rodents, but only CB3 transcripts are evident in humans. D, Schematic diagram of the primary structures of known
collybistin isoforms. Sequences encoding the SH3, RhoGEF, and PH domains in the collybistin isoforms are indicated by gray boxes,
and the different C termini are indicated by white (CB1), black (CB2), or gray (CB3) boxes. E, Expression of myc-tagged CB2SH3 in
HEK293 cells. F, G, Cotransfection of a plasmid construct encoding EGFP-gephyrin results in the formation of cytoplasmic aggre-
gates ( F) to which myc-CB2SH3 targets ( G). However, coexpression of EGFP-gephyrin with the CB2 variant lacking the SH3
domain (myc-CB2SH3) results in a redistribution of EGFP-gephyrin and collybistin to submembrane microaggregates ( H, I ).
Scale bar, 10m. Note that E–G are single Z-plane confocal images, whereas H and I are Z-stacks at the cell surface.
Figure 2. A DsRed-GlyR fusion protein is efficiently targeted to EGFP-gephyrin aggregates
in HEK293 cells. Z-stack confocal images showing triple transfection of HEK293 cells with plas-
mid constructs encoding a DsRed-GlyR  subunit intracellular loop fusion protein (A; DsRed-
GlyR), EGFP-gephyrin ( B), and myc-CB2SH3 ( C). Note that DsRed-GlyR is readily trapped
by EGFP-gephyrin submembrane clusters, whereas myc-CB2SH3 has a more diffuse distribu-
tion pattern throughout the cytoplasm ( D). Scale bar, 10m.
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tively competes with endogenous collybis-
tin for binding to gephyrin, causing mislo-
calization of endogenous gephyrin (Fig.
3 J,K, arrows). Note that dendrites of non-
transfected control cells demonstrated ro-
bust gephyrin clustering (Fig. 3J).
Mapping of binding sites for collybistin
and the GlyR subunit on gephyrin
Although the binding sites for gephyrin on
collybistin and the GlyR  subunit have
been described previously (Kneussel et al.,
1999a; Grosskreutz et al., 2001), the corre-
sponding binding sites on gephyrin have
remained elusive. Several studies have sug-
gested that the binding site for the GlyR 
subunit lies within the N-terminal MogA
domain (Meier et al., 2000; Schwarz et al.,
2001; Xiang et al., 2001) or the “linker re-
gion” of gephyrin (Prior et al., 1992).
However, these studies are complicated by
the fact that the MogA domain forms tri-
mers (Sola et al., 2001; Schwarz et al.,
2001), whereas the C-terminal MoeA do-
main probably dimerizes in a manner simi-
lar to the E. coli MoeA protein (Schrag et al.,
2001; Xiang et al., 2001). To define the re-
gions involved in collybistin-gephyrin and
GlyR -gephyrin interactions, we used the
GAL4 yeast two-hybrid system (Fields and
Song, 1989). Full-length rat gephyrin (P1
isoform) (Prior et al., 1992) interacted
readily with baits for CB2SH3 and the large
intracellular loop of the human GlyR sub-
unit (Rees et al., 2003) (Fig. 4A). N-terminal
truncations of gephyrin lacking the MogA
domain and the linker region revealed nor-
mal interaction with the GlyR-subunit bait
(deletions 92, 184, 276, 305, and 323) (Fig.
4A). The same gephyrin constructs, except
deletion 323, also showed normal interac-
tion with the CB2SH3 bait (Fig. 4A,B). This
finding is significant, because the GlyRbait
shows a strong interaction with deletion 323,
indicating that this gephyrin fragment is indeed expressed in yeast
(Fig. 4A,B). Deletions at either end of the MoeA homology domain
of gephyrin (deletions 336, 643, 674, or 704) abolished both
CB2SH3 and GlyR  subunit interactions. A bait corresponding to
the MoeA homology domain of gephyrin revealed that although
deletions 305 and 323 showed strong MoeA–MoeA interactions
(Fig. 4B), deletions 336, 643, 674, and 704 either impaired or abol-
ished MoeA–MoeA multimerization.
Because deletions 305 and 323 appeared to demarcate a region
important for collybistin-gephyrin interactions, we used an ala-
nine mutation scan across this region to further define the amino
acids involved. This revealed that mutants A4 and A5, which
together span the short peptide sequence PFPLTSMDKA (Fig.
4C,D), disrupted collybistin-gephyrin interactions without affecting
the GlyR -gephyrin interaction. It is noteworthy that the P-F-P
motif at the beginning of the putative collybistin-binding motif is
lost in the deletion construct 323 (Fig. 4D). Mutation of residues
flanking the PFPLTSMDKA motif (mutants Geph-A3 and Geph-
A6) did not affect collybistin-gephyrin or GlyR -gephyrin interac-
tions in yeast (Fig. 4C,D). To test whether the A4 and A5 alanine
mutants disrupted collybistin-gephyrin colocalization in mamma-
lian cells, we next introduced these mutations into pEGFP-gephyrin.
These mutations were sufficient to either disrupt (EGFP-GephA4)
or severely weaken (EGFP-GephA5) collybistin-gephyrin colocal-
ization (Fig. 4E) after coexpression with myc-CB2SH3 in HEK293
cells. In addition, submembrane targeting was abolished for both
EGFP-A4 and EGFP-A5 (Fig. 4E).
Expression of EGFP-gephyrin in transfected cortical neurons
resulted in punctate staining throughout dendritic processes
(Fig. 5A), which colocalizes with staining for mAb7a (gephyrin)
and GAD (Fig. 5E). However, when neurons were transfected
with the EGFP-GephA4 mutant, dendritic puncta were dramat-
ically reduced. Two main phenotypes were noted: either gephyrin
accumulated in large aggregates in the cell soma (Fig. 5B) or cell
soma plus dendrites (Fig. 5C). These gephyrin aggregates were no
longer juxtaposed to GABAergic terminals (Fig. 5F,G). There-
fore, EGFP-GephA4 acts as a dominant-negative factor trapping
endogenous gephyrin and preventing proper apposition of pre-
Figure 3. Functional collybistin is required for accumulation of gephyrin in dendritic clusters. A–E, Expression of myc-tagged
CB2SH3 ( A, C) and CB2SH3 ( B, D) isoforms in transfected mouse cortical neurons reveals a diffuse distribution throughout the
cell soma and dendrites (see enlargements in C and D) without affecting gephyrin cluster number (E; values are mean SE).
Constructs lacking the RhoGEF or PH domains (inset) were coexpressed with EGFP-gephyrin in HEK293 cells. F, G, Single Z-plane
confocal images show that myc-CB2SH3 RhoGEF mutant no longer colocalizes with EGFP-gephyrin and prevents submem-
brane targeting. H, I, In contrast, the myc-CB2SH3PH mutant colocalizes with EGFP-gephyrin but also results in the production
of cytoplasmic collybistin-gephyrin microclusters. Note that gephyrin and collybistin aggregates in F–I are intracellular, because
the cell nucleus is clearly visible in each single optical section. J, K, In transfected mouse cortical neurons, myc-CB2SH3 PH acts
as a dominant-negative factor, competing with endogenous collybistin for binding sites on gephyrin. Quantitative analysis of
mAb7a staining indicates a statistically significant loss of dendritic gephyrin clusters (E; *p	 0.001; Student’s t test; n 10 –11
cells per construct) and accumulation of endogenous gephyrin in aggregates in the proximal dendrites (white arrow). Scale bars:
A, B, 22m; C, D, 11m; F–I, 5m; J, 23m; K, 11.5m.
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synaptic and postsynaptic structures. In contrast, mutant EGFP-
GephA5 shows a few large dendritic clusters and appears to trap
endogenous gephyrin at these sites (Fig. 5D,H). Quantitative
analysis (Fig. 5I) demonstrated that the average endogenous
gephyrin cluster number (mAb7a immunofluorescence) was re-
duced to 2 1.95 clusters per 40 m segment per cell for EGFP-
GephA4 (n  12 neurons) and 4.63  2.01 clusters for EGFP-
GephA5 per 40 m segment per cell. These results were
statistically significant when compared with EGFP-gephyrin,
which showed an average of 9.77  2.74 clusters per 40 m
segment per cell (n 13 neurons; p	 0.001; Student’s t test). In
summary, both EGFP-GephA4 and EGFP-GephA5 mutants ef-
fectively interfere with clustering of endogenous gephyrin in
transfected cortical neurons. As in HEK293 cells (Fig. 4E), mu-
tant EGFP-GephA4 is particularly effective, leading to a fivefold
reduction of endogenous gephyrin clusters.
ARHGEF9 as a candidate gene
for hyperekplexia
Hereditary hyperekplexia is a neurological
disorder characterized by an excessive
startle response, which can be caused by
diverse dominant and recessive mutations
in the genes encoding the GlyR 1
(GLRA1) (Rees et al., 2001) or  subunits
(GLRB) (Rees et al., 2002). However, a sig-
nificant portion of patients with hyperek-
plexia does not appear to have mutations
in either GLRA1 (Vergouwe et al., 1997) or
GLRB (Rees et al., 2002), suggesting that
other components of the GlyR signaling
complex, such as gephyrin (GPHN) (Rees
et al., 2003) and collybistin (gene symbol:
ARHGEF9) may be involved. ARHGEF9
consists of 10 exons distributed over190
kb of human chromosome Xq22.1 (Fig.
6A; supplemental Table 1, available at
www.jneurosci.org). EST analysis revealed
the existence of two alternative first exons
(denoted exons 1a and 1b) (supplemental
Table 1, available at www.jneurosci.org),
suggesting that ARHGEF9 has two pro-
moters that might control tissue-specific
or developmentally regulated changes in
gene expression. Exon 1a encodes a long N
terminus (MQWIRGGSGM), whereas
exon 1b encodes a shorter sequence
(MTL). Exons 1a and 1b do not appear to
influence utilization of exon 2, which en-
codes the SH3 domain (data not shown).
We used PCR (primers listed in sup-
plemental Table 2, available at www.
jneurosci.org) and automated dHPLC to
detect ARHGEF9 mutations and polymor-
phisms in a cohort of 32 hyperekplexia pa-
tients. Two SNPs were detected in the in-
tronic regions of exon 1b (IVS2  43 tc;
het  0.05) and exon 10 (IVS11  64 tc;
het  0.04) in both male and female pa-
tients and control cohorts. Significantly, a
missense mutation (G164C) in the ARH-
GEF9 coding region was discovered in one
patient, which causes a glycine to alanine
(G55A) substitution at position 55 of
hPEM-2 (Fig. 6B,C, inset). The mutant genotype creates a NlaIII
restriction site (5-GATG-3 to 5-CATG-3), a situation which
was not detected in over 200 unrelated Caucasian control chro-
mosomes (Fig. 6D). A glycine residue is found at the equivalent
position in 97% of known SH3 domains (2580/2669) as assessed
by using psiBLAST (www.biology.wustl.edu/gcg/psiblast.html)
against the National Center for Biotechnology Information non-
redundant database. A molecular model of the SH3 domain
structure (Fig. 6E) shows that the G55A substitution lies in the
middle of a  strand, and that this position of the protein back-
bone has Phi/Psi angles just beyond the limits of what is normally
allowed for a nonglycine amino acid. G55A lies proximal to one
of a series of residues that has been implicated in binding the
proline-rich motif (Fig. 6B).
The patient was the first-born child of a 32-year-old woman,
delivered in the thirty-sixth week of gestation. Immediately after
Figure 4. Mapping of the collybistin binding site on gephyrin. A, Deletion constructs of the rat gephyrin P1 isoform in pACT2
(Clontech) were tested using the GlyR subunit intracellular loop () and full-length collybistin CB2SH3 isoform (CB2) as baits.
Both proteins interact with full-length gephyrin in yeast, as judged by a semiquantitative LacZ assay (, strong interaction;
, weak interaction; —, no interaction). Deletion analysis indicated that the gephyrin MogA domain (MogA) and most of the
linker region do not appear to contribute to either GlyR subunit or collybistin binding. Deletions into the gephyrin MoeA domain
(MoeA) destroy interactions with both collybistin and the GlyR subunit because of the loss of MoeA–MoeA domain interactions.
B, Geph-305 interacts with GlyR, CB2SH3, and MoeA domain baits, whereas Geph-323 (which corresponds to a MoeA domain
prey) interacts with GlyR and MoeA but not CB2SH3. C, D, Mutants (Geph-A1 to Geph-A7), which span the Geph-305 to Geph
323 region, were then constructed and tested in yeast assays. Mutations Geph-A4 and Geph-A5 (boxed) abolished interactions
with CB2SH3 but not the GlyR  subunit (C, D). The corresponding mutants in EGFP-gephyrin eliminated (EGFP-GephA4) or
weakened (EGFP-GephA5) colocalization with myc-CB2SH3 ( E) and blocked submembrane microaggregate formation. Scale
bar, 10m.
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delivery, cyanosis and muscular stiffness
(suggestive of muscular hypertonia) were
noted. The child also appeared to stare.
During the following weeks, the child de-
veloped tonic seizures that were provoked
by tactile stimulation. To counter the sei-
zures, initially phenobarbital and then la-
motrigene were administered. Although
the latter treatment was initially effective,
after three and one-half months of age, the
seizures recurred and were often precipi-
tated by extreme emotions. At 4 months of
age, a diagnosis of hyperekplexia was
made, but therapy with clonazepam was
unsuccessful. EEG monitoring coupled
with ambulatory video revealed that the
seizures were both hyperekplectic and ep-
ileptic in origin. During the following
years, the child suffered from frequent
long-lasting seizures, accompanied by the
arrest and later decline of psychomotor
development. Eventually, a progressive
epileptic encephalopathy as well as hy-
perekplexia became evident and poly-drug
treatment failed to provide adequate long-
term seizure control. At four years of age,
the subject was severely retarded and suf-
fered almost daily severe long-lasting fits
both epileptic and nonepileptic in origin,
eventually leading to death at the age of 4 years and 4 months.
Functional analysis of the G55A mutation
The clinical symptoms above are consistent with a mislocaliza-
tion of neuronal gephyrin and associated glycine and GABAA
receptors. We therefore assessed possible functional consequences of
the G55A mutation. Unlike myc-CB2SH3 (Fig. 1G) or myc-
CB3SH3 (Fig. 6F), myc-CB3SH3G55A did not colocalize with large
cytoplasmic EGFP-gephyrin aggregates in transfected HEK293 cells,
but like myc-CB2SH3 (Fig. 1I), myc-CB3SH3G55A translocated
gephyrin to submembrane microaggregates (Fig. 6G). This result
suggests that the G55A mutation disrupts the SH3 domain structure
and function. In cortical neurons, wild-type myc-CB3SH3 is dif-
fusely expressed within the soma and proximal and distal dendrites
and does not influence endogenous gephyrin clustering (Fig. 6H–
J,Q). The average gephyrin cluster number was 11.9 4.44 per 40
m dendritic segment (n 11 neurons) for myc-CB3SH3. In con-
trast, myc-CB3SH3G55A forms a tight association with endoge-
nous gephyrin and is confined to the cell soma and proximal den-
drites, indicating a deficit in dendritic trafficking of this mutant
protein (Fig. 6 K–M ). In another subset of cells, myc-
CB3SH3G55A is found in large somatic and dendritic aggregates
(Fig. 6N–P), which results in an almost complete loss of gephyrin
clusters. Quantitative analysis of gephyrin clustering shows that
expression of myc-CB3SH3G55A results in a dramatic loss of
endogenous gephyrin clusters (Fig. 6Q). The average cluster
number (mAb7a immunofluorescence) was reduced to 1.55 
0.72 clusters per 40m segment per cell for myc-CB3SH3G55A,
which is statistically significant compared with myc-CB3SH3
(n 11 cells per construct; p	 0.001; Student’s t test).
To address possible functional consequences at inhibitory synapses,
we assessed whether transfection of myc-CB3SH3G55A would affect
postsynaptic localization of GABAA receptors. Triple staining of
neurons transfected with myc-CB3SH3 with antibodies specific
for this construct, for GABA terminals (GAD) and for the GABAA
receptor 2 subunit revealed, as expected, diffuse distribution of
this collybistin isoform and proper localization of GABAA recep-
tors at postsynaptic sites (Fig. 7A–D). Enlargement of a dendritic
segment (Fig. 7E–H) shows clear colocalization of GABAA recep-
tors (red) and GAD (blue) resulting in purple puncta (Fig. 7H,
arrows). In contrast, in neurons transfected with myc-
CB3SH3G55A, GABAA receptors were essentially absent from
the dendritic compartment (Fig. 7I–P). Quantitative analysis of
GABAA receptor clustering (Fig. 7Q) shows that the average clus-
ter number was reduced to 2.08  1.29 clusters per 40 m seg-
ment per cell for myc-CB3SH3G55A, which is statistically signif-
icant when compared with 10.04  1.57 clusters for myc-
CB3SH3 (n 12 cells per construct; p	 0.001; Student’s t test).
This mislocalization of GABAA receptors, together with a corre-
sponding expected deficit in glycine receptor trafficking in brain
stem and spinal cord neurons, is likely to be causal for the clinical
phenotype of the patient described above.
Discussion
The dendritic trafficking of receptors and clustering at appropri-
ate sites in the postsynaptic membrane are extremely important
events in the formation of functional synapses. This study reveals
that the RhoGEF collybistin is a key molecule in regulating syn-
aptic localization of gephyrin and by association, GABAA and
glycine receptors. First, we reported the characterization of new
variants of collybistin, which are created by alternative splicing of
exons encoding an N-terminal src homology 3 domain and three
alternate C termini (CB1, CB2, and CB3). Secondly, we have
shown that the SH3 domain negatively regulates the ability of
collybistin to translocate gephyrin to submembrane microaggre-
gates in HEK293 cells. Because most endogenous collybistin iso-
forms harbor this region, this strongly suggests that collybistin
activity is regulated by protein–protein interactions at the SH3
Figure 5. Disruption of the collybistin binding site on gephyrin prevents accumulation of gephyrin at postsynaptic sites. A–H,
EGFP-tagged gephyrin ( A, E) and the mutants EGFP-GephA4 ( B, C, F, G) and EGFP-GephA5 ( D, H ) were transfected into cortical
neurons and the cells immunostained for gephyrin (mAb7a; A–D) or GAD (mAbGAD-6; E–H ). Two examples of cells are shown for
EGFP-GephA4 representing comparatively low ( B, F ) and high (C, G) levels of expression and corresponding aggregate pheno-
types. Note the perfect colocalization of transfected EGFP-gephyrin with endogenous gephyrin in yellow puncta ( A). The few
remaining red puncta indicate endogenous gephyrin expressed on dendrites of nontransfected neighboring cells that are there-
fore not colocalized with EGFP-gephyrin. EGFP-gephyrin is localized at postsynaptic sites juxtaposed to presynaptic GAD (E,
arrows). Mutants EGFP-GephA4 and EGFP-GephA5 form large aggregates in the soma and dendrites, which are no longer juxta-
posed to GABAergic terminals ( F–H). Endogenous gephyrin has been trapped in these extrasynaptic gephyrin mutant aggregates,
which therefore appear yellow ( B–D). Quantitative analysis of mAb7a staining indicates a statistically significant loss of synaptic
gephyrin clusters (I; *p	 0.001; Student’s t test; n 12–13 cells per construct) for the EGFP-GephA4 and EGFP-GephA5 mutants
compared with EGFP-gephyrin. Scale bar, 20m.
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domain. Other functional domains of collybistin are also crucial,
because gephyrin clustering requires both collybistin-gephyrin
interactions and an intact collybistin PH domain. Third, we
mapped the binding sites for collybistin and the GlyR  subunit
on gephyrin to the C-terminal MoeA homology domain and
show that multimerization of the MoeA domain is a requirement
for both collybistin-gephyrin and GlyR-gephyrin interactions.
Last, we present the first significant genetic evidence that col-
lybistin is important for the correct synaptic targeting of
gephyrin: a G55A mutation in exon 2 of the human collybistin
gene (ARHGEF9) results in symptoms of
both hyperekplexia and epilepsy, which
is likely to be caused by mislocalization
of gephyrin and associated GlyR and
GABAA receptors.
Functional significance of collybistin
alternative splicing
In addition to the original rat collybistin
isoforms (now denoted CB1SH3 and
CB2SH3), we cloned two additional iso-
forms (CB2SH3 and CB3SH3) from neo-
natal rat brain. We also determined that
the CB2 and CB3 isoforms are of equal
abundance in postnatal rat or mouse brain
(CB1 was not detected), and that in adult
human spinal cord and brain, CB3SH3
(but not CB1 or CB2) was detected. Alterna-
tive splicing of N- and C-terminal exons in-
dicates that care must be applied in inter-
preting studies using in situ hybridization
(Kins et al., 2000; Kneussel et al., 2001a) or
when generating collybistin-specific anti-
sera. The finding that CB2SH3 and
CB3SH3 are functionally inactive in recom-
binant gephyrin clustering assays is a para-
dox, because the vast majority of spliced
transcripts in rat, mouse, and human spinal
cord or brain clearly seem to encode these
isoforms. It appears that collybistin activity is
regulated via protein–protein interactions or
post-translational modifications at the SH3
domain and that this mechanism only oper-
ates correctly in neurons. In this model, col-
lybistin could be “activated” at specific sub-
cellular locations by an SH3-interacting
ligand or “trigger protein.”
Functional collybistin is required for
dendritic clustering of gephyrin
By overexpressing recombinant collybistin
isoforms and mutants in cortical neurons,
we demonstrated that collybistin is an es-
sential molecule for dendritic gephyrin
clustering and for appropriate trafficking
of GABAA receptors to synapses. A similar
role for collybistin is likely at glycinergic
synapses of brainstem and spinal cord
neurons. The distribution of epitope-
tagged collybistin in neurons suggested
that the protein is present at, but not lim-
ited to, synaptic sites. Analyses of the ex-
pression pattern of the PH domain dele-
tion mutant, CB2SH3 PH, suggested
that collybistin is involved in dendritic transport of gephyrin to
inhibitory synapses. Deletion of the PH domain resulted in accu-
mulation of endogenous gephyrin in proximal dendrites and sig-
nificantly reduced endogenous gephyrin clustering. Whether this
mutation disrupts PH domain-membrane phosphoinositide
interactions, or the binding of one or more key collybistin-
interacting proteins, remains to be determined. The RhoGEF
domain deletion also disrupted submembrane targeting of
gephyrin; this is likely because of the fact that CB2SH3 Rho-
Figure 6. Mutation of G55A in a patient with hyperekplexia and epilepsy. A, Genomic structure of the human collybistin gene
(ARHGEF9) encoding hPEM-2. B, The location of the mutation G55A (red lettering) in the N-terminal SH3 domain (underlined) of
hPEM-2 is shown. G55A lies proximal to one of the series of residues that have been proposed to bind proline-rich motifs (blue
lettering). C, DNA sequencing of exon 2 samples revealed a G to C substitution at position 164 of the collybistin coding sequence,
causing a G55A missense mutation in the N-terminal SH3 domain of hPEM2. G164, Control sample; G164G164C, ad-mixture of
the patient sample with a female DNA control; G164C, G164C mutation. D, Restriction fragment length polymorphism analysis of
the G55A mutation: the G164C mutation creates a novel NlaIII site at position 207 of the 313 bp exon 2 PCR fragment. This, in
conjunction with another NlaIII site at position 106, generates convergent fragments of 106, 101, and 106 bp in the patient DNA
sample (denoted P). Normal controls (C1–C4) have fragments of 207 and 106 bp. E, A molecular model showing the location of
G55 in the SH3 domain structure calculated with Swiss-Model (Guex and Peitsch, 1997). F, G, Confocal images showing HEK293
cells transfected with plasmid constructs for myc-CB3SH3 and EGFP-gephyrin ( F) or myc-CB3SH3G55A and EGFP-gephyrin ( G).
Note that myc-CB3SH3 colocalizes with cytoplasmic EGFP-gephyrin aggregates, whereas myc-CB3SH3G55A results in submem-
brane microclusters of EGFP-gephyrin. H–P, Confocal images showing myc-CB3SH3 ( H–J) and myc-CB3SH3G55A ( K–P) ex-
pressed in cultured cortical neurons. Although wild-type myc-CB3SH3 ( H ) is expressed throughout the cell soma and dendrites
and does not disrupt gephyrin localization ( H–J), myc-CB3SH3G55A forms a tight association with endogenous gephyrin in
clusters confined to proximal dendrites ( K–M). In a subset of transfected cells ( N–P), myc-CB3SH3G55A forms large somatic and
dendritic aggregates, which results in an almost complete loss of gephyrin clusters. Remaining red puncta in I, L, and O represent
gephyrin clusters from nontransfected cells in the same culture. Quantitative analysis of mAb7a immunofluorescence ( Q) indi-
cates a dramatic loss of gephyrin clusters (*p	 0.001; Student’s t test; n 11 cells per construct) for myc-CB3SH3G55A mutant
compared with myc-CB3SH3. Scale bars: F, G, 10m; H–P, 35m.
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GEF no longer interacts with gephyrin,
rather than deficits in GDP-GTP exchange.
Interaction of collybistin and GlyR
with gephyrin requires
MoeA–MoeA interactions
A C-terminal fragment encompassing
amino acids 305–736 of gephyrin dis-
played robust binding to collybistin and
gephyrin, meaning that all of the
N-terminal MogA homology domain
(amino acids 16 –169) and most of the in-
tervening linker region (amino acids 170 –
322) are dispensable for binding these
molecules. Furthermore, our results
with deletion constructs indicated that
the binding site for GlyR  must reside
entirely within the MoeA homology do-
main (amino acids 323–736). If the
gephyrin MoeA homology domain
forms an antiparallel dimer, like E. coli
MoeA (Mene´ndez et al., 1997; Schrag et
al., 2001; Xiang et al., 2001), our results
strongly suggest that two equivalent
GlyR  binding sites would be present at
the MoeA–MoeA homology domain in-
terface. Whether these two equivalent sites
would bind a single GlyR heteromer, which is thought to contain
two  subunits (stoichiometry 132) or two distinct receptor
pentamers, is presently unclear. Localization of the residues on
gephyrin that interact with GlyRs will probably require cocrystal-
lization of the MoeA homology domain with a peptide corre-
sponding to the gephyrin-binding site on the GlyR  subunit
(Kneussel et al., 1999a). Caution must be exercised with the anal-
ysis of mutants that disrupt gephyrin-GlyR  subunit interac-
tions, because these may simply be defective in MoeA–MoeA
assembly. Ideally, a gephyrin mutant defective in GlyR  subunit
binding would retain robust MoeA–MoeA interactions and
would be translocated to submembrane microaggregates by
collybistin.
A putative binding site for collybistin was located to the bor-
der of the linker region and MoeA domain. Replacement of two
adjacent groups of five amino acids either completely abolished
(Geph-A4) or reduced (Geph-A5) collybistin-gephyrin interactions
in HEK293 cells but did not affect interaction with the GlyR  sub-
unit. When expressed in cortical neurons, EGFP-gephyrin was lo-
calized at synaptic sites. This was evidenced by the almost perfect
concordance of EGFP-gephyrin fluorescence and mAb7a immu-
noreactivity, the latter representing both transfected and endog-
enous gephyrin and by the close apposition of EGFP-gephyrin and
presynaptic immunoreactivity for GAD. In contrast, the gephyrin
A4 and A5 mutants were both confined to large somatic and den-
dritic aggregates. These aggregates were not apposed to GAD immu-
noreactivity, indicating they were mislocalized. Quantitative analy-
ses showed that punctate immunoreactivity for endogenous
gephyrin in these transfected cells was severely reduced for EGFP-
GephA4 and, to a lesser extent, for EGFP-GephA5. Interestingly, in
cells expressing high levels of the EGFP-GephA4 mutant, the mutant
and endogenous gephyrin proteins were both confined to large
structures that extended far into peripheral dendrites. Thus,
EGFP-GephA4 is effectively transported to peripheral den-
drites, although it cannot by itself interact with colly-
bistin. However, some collybistin-dependent trafficking func-
tion may be provided indirectly through multimerization of
the mutant gephyrin construct with endogenous gephyrin,
which remains likely to interact with collybistin. In compari-
son, EGFP-GephA5 aggregates were smaller and more con-
fined to the soma and proximal dendrites of transfected neu-
rons. Our study identifies a critical sequence in gephyrin
(PFPLTSMDKA) that appears to be essential for collybistin-
gephyrin interactions and for normal collybistin-mediated
trafficking and clustering of gephyrin to postsynaptic sites.
G55A mutation in the hPEM2 SH3 domain leads to
hyperekplexia and epilepsy
The importance of collybistin for postsynaptic localization of
gephyrin and associated ligand-gated chloride channels is under-
lined by the effect of the G55A mutation in the SH3 domain,
leading to symptoms of both hyperekplexia and epilepsy. Recent
studies (Douangamath et al., 2002; Groemping et al., 2003; Liu et
al., 2003) have shown that there is sometimes binding of ligands
to SH3 domains beyond the proline-rich peptide binding region.
However, because the conserved glycine is buried within the SH3
domain structure, we consider that disrupting SH3 domain fold-
ing rather than the binding surface is the most probable mecha-
nism of action. This is supported by studies in transfected
HEK293 cells, revealing that the G55A mutation deregulates SH3
domain-containing collybistin isoforms, allowing translocation
of gephyrin to submembrane sites in HEK293 cells. However, it is
noteworthy that in neurons, myc-CB3SH3G55A differs dramat-
ically from other recombinant collybistin isoforms, including
myc-CB2SH3, which lacks the SH3 domain. CB3SH3G55A
forms a tight association with gephyrin in dendritic clusters or
forms large somatic and dendritic aggregates. These findings sug-
gest that the G55A mutation causes a more complex deficit in
dendritic trafficking of collybistin and disrupts collybistin–acces-
sory protein interactions. The severe functional consequences of
this mutation for the synaptic localization of gephyrin and, by
Figure 7. Collybistin mutant CB3SH3G55A results in loss of GABAA receptor clusters. Triple staining of neurons transfected
with either myc-CB3SH3 ( A–H) or myc-CB3SH3G55A ( I–P) with antibodies against the GABAA receptor2 subunits (red), myc
tag (green), and GAD (blue). Note that in myc-CB3SH3-transfected neurons ( A–D), GABAA receptor clusters are juxtaposed to
GAD-positive terminals (a selected dendritic region is enlarged in images E–H ). Overlap of GABAA receptor and GAD immunore-
activity appears pink in the merged image (H, arrows). In contrast, in neurons expressing myc-CB3SH3G55A, GABAA receptor
immunoreactivity is primarily confined to the cell soma ( I, M ), and large collybistin aggregates ( J, N ) are observed throughout the
dendrites.NotethatthesecollybistinaggregatesarenotjuxtaposedtoGABAergicterminals( K, L,O,P).Quantitativeanalysisof2subunit
immunofluorescence ( Q) indicates a statistically significant loss of GABAA receptor clusters (*p	0.001; Student’s t test; n12 cells per
construct) for the myc-CB3SH3G55A mutant compared with myc-CB3SH3. Scale bars: A–D, I–L, 25m; E–H, M–P, 12.5m.
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association, GABAA receptors strongly suggest that the clinical
phenotype observed in this patient was a consequence of the loss
of gephyrin and major GABAA and GlyR subtypes from synaptic
sites. Although gene targeting experiments in mice have previ-
ously suggested that loss of gephyrin would be lethal in the first
postnatal days, gephyrin is not only required for synaptic cluster-
ing of GABAA and GlyRs (Feng et al., 1998; Kneussel et al., 1999b,
2001b; Levi et al., 2004) but also for molybdoenzyme activity in
non-neuronal tissues. Overall, we predict that mutations affect-
ing collybistin function result in a neuronal gephyrin phenotype,
whereas peripheral molybdoenzyme-related functions of
gephyrin are left undisturbed. The possibility remains that
additional mutations in ARHGEF9 may contribute to other
cases of X-linked hyperekplexia and epilepsy.
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